SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as the community discusses the launch of the $DOJE ETF, with some anticipating significant price movement. Talk centers around potential accumulation strategies and whether the ETF will trigger a major rally, although the launch may be delayed. There's also discussion around Dogecoin's long-term value and comparisons to other cryptocurrencies.

The project is a derivative of Fartcoin. The Fartcoin deployer has deployed this token because the President at Bone Fide Wealth tweeted about "A client just called and asked me if there’s going to be a Fartcoin ETF this year." Since the Elon narrative is has been running this one has come to existence. The token is following different narratives like Fartcoin, SPX500 and other big memes following the Trump narrative.

Elon Trump Fart

ETF500.X is trending as the community rallies, emphasizing its strength and long-term vision, particularly after the CEO departure. Discussions highlight the token as Solana's first ETF, with many proclaiming it as the best ETF ever. The community is focused on accumulation, anticipating a significant move.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group (DJT) is trending amid heated discussions around the political motivations behind a recent tragedy, sparking intense debate within the community.  Users are clashing over affiliations and broader cultural grievances, with some pointing fingers and others calling for unity. The conversation highlights the deep divisions and sensitivities surrounding the symbol and its association with political figures.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

aTyr Pharma ($ATYR) is trending as traders anticipate Phase 3 data for its lead drug, efzofitimod, in mid-September, creating a high-stakes binary event. The community is buzzing with debate around the trial's design, potential outcomes, and the influence of figures like Martin Shkreli, with some expecting a short squeeze if results are positive. Bullish sentiment is fueled by recent analyst ratings and commercial hires, while bears point to past trial data and high implied volatility.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

PEPE.X is trending as the community speculates on potential rallies and discusses strategies to push the price higher, with some eyeing the possibility of revisiting all-time highs. Community members are actively sharing bullish sentiments and engaging in meme-based discussions, while also debating the token's potential within the broader meme coin landscape, comparing it to other popular cryptocurrencies like DOGE.X and SHIB.X.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as traders discuss potential volatility catalysts, including upcoming economic data and geopolitical tensions. Community members are weighing the potential for a market correction against the effects of contango on the ETF. Some traders are using UVIX to hedge long positions or speculating on short-term price movements.

Volatility Shares Trust - 2x Bitcoin Strategy ETF

Volatility Shares 2x Bitcoin Strategy ETF

BITX is trending as traders assess Bitcoin's potential near all-time highs and its impact on leveraged ETFs. Community discussions revolve around market volatility, technical analysis, and the broader implications of economic policies. Concerns about potential market corrections and the influence of external factors such as political events are also driving interest in BITX.

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.

GlucoTrack Inc

GCTK is trending due to a recent $20 million investment agreement, sparking community discussion about its potential impact and whether it signals a true turning point or further dilution. Community members are actively trading the stock, anticipating significant price movement based on the low float and upcoming conference, with some looking for a short squeeze. The stock is also being compared to other high-flying low floaters.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include Core, Cognitive Adjacencies, and Network Software and Services. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Arista Networks is trending as the stock experiences volatility amidst analyst upgrades and price target adjustments, leading to community debate on its near-term direction. Discussions revolve around recent price drops being potential profit-taking opportunities or possible manipulation, while others point to strong data center growth prospects and AI networking as long-term bullish factors. Community members are actively trading options and debating entry points, particularly around key technical levels.

The ODP Corp. is a holding company, which engages in the provision of business services and supplies, products, and digital workplace technology solutions. It operates through the following segments: ODP Business Solutions Division, Office Depot Division, and Veyer Division. The ODP Business Solutions Division acts as a B2B distribution solutions provider serving small, medium, and enterprise level companies, including those in the public and education sectors. The Office Depot Division offers retail consumer and small business products and services distributed through a fully integrated omni-channel platform of 869 Office Depot and OfficeMax retail. The Veyer Division consists of supply chain, distribution, procurement, and global sourcing operation, which specializes in B2B and consumer business service delivery, with core competencies in distribution, fulfillment, transportation, global sourcing and purchasing. The company was founded in 1986 and is headquartered in Boca Raton, FL.

ODP Corporation (The)

ODP is trending due to a mix of factors including new share repurchase authorizations and discussion around the potential sale of its consumer business. The company recently reported earnings and detailed a path to unlocking earnings potential with newly realigned business units, which has sparked conversation within the investment community. Community members are also discussing the stock's valuation and technical indicators.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout

Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet

MoonLake Immunotherapeutics, a clinical-stage biotech firm valued at $2.6 billion, is generating excitement with its experimental treatment for hidradenitis suppurativa (HS), a chronic and painful skin condition.&nbsp;On Friday, Goldman Sachs upgraded the stock to a&nbsp;'Buy' from&nbsp;'Neutral,' with analyst Richard Law raising the price target from $62 to $82 — an 85% upside from current levels, CNBC&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/01/17/this-little-known-biotech-stock-is-a-buy-thats-primed-to-double-in-price-goldman-says.html">reported</a>.While MoonLake is gaining traction among institutional investors, it remains underfollowed on Stocktwits, with fewer than 600 watchers.&nbsp;Over the past year, retail interest has been budding, with a 12% increase in followers, even as the stock has fallen 26%.Law reportedly believes MoonLake's experimental nanobody treatment, sonelokimab (SLK), holds transformative potential.&nbsp;SLK demonstrated impressive efficacy in phase 2 trials, leading to optimism about its success in phase 3.&nbsp;Additionally, SLK's inclusion of AbbVie's Skyrizi — currently the standard of care for psoriatic arthritis (PsA) — as a reference treatment offers a key differentiator, according to the analyst.Law suggests that while this adds some risk, the potential to position SLK as superior in a competitive market far outweighs the drawbacks.Goldman Sachs isn't alone in its optimism. Oppenheimer included MoonLake among its top biotech picks for 2025, alongside Capricor, Gilead, Kymera, Praxis, and Prothena.&nbsp;The brokerage sees biotech equities as undervalued relative to other sectors, with strong catalysts like lower interest rates, robust M&amp;A prospects, and transformative data releases creating a favorable backdrop this year.MoonLake ended the third quarter (Q3) of 2024 with $493.9 million in cash, cash equivalents, and marketable securities, which the company said provides a runway through 2026.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Over the past year, retail interest has been budding, with a 12% increase in followers, even as the stock has fallen 26%.

Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely?

Oppenheimer has included MoonLake among its top biotech picks for 2025, alongside Capricor, Gilead, Kymera, Praxis, and Prothena.

Equity

Buy Rating for MoonLake Immunotherapeutics Backed by Strong Prospects for Lead Candidate and Financial Stability

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on MoonLake Immunotherapeutics (MLTX Research Report). The associated p...

TimesSquare Capital Management LLC Has $23.44 Million Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)

TimesSquare Capital Management LLC raised its holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX  Free Report) by 1,270.7% in the 3rd quarter, according to the company in its most recent...

MoonLake announces significant improvements with Nanobody  sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

MoonLake announces significant improvements with Nanobody sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day Positive 24-week data from the...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Forecasted to Earn Q1 2024 Earnings of ($0.30) Per Share

MoonLake Immunotherapeutics (NASDAQ:MLTX  Free Report)  Analysts at HC Wainwright raised their Q1 2024 earnings estimates for MoonLake Immunotherapeutics in a note issued to investors...

HC Wainwright Weighs in on MoonLake Immunotherapeutics' Q1 2025 Earnings (NASDAQ:MLTX)

MoonLake Immunotherapeutics (NASDAQ:MLTX  Free Report)  HC Wainwright issued their Q1 2025 earnings estimates for shares of MoonLake Immunotherapeutics in a research note issued on...

FY2028 Earnings Estimate for MoonLake Immunotherapeutics (NASDAQ:MLTX) Issued By Leerink Partnrs

MoonLake Immunotherapeutics (NASDAQ:MLTX  Free Report)  Stock analysts at Leerink Partnrs lifted their FY2028 earnings per share (EPS) estimates for shares of MoonLake...

Wedbush Reaffirms Outperform Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)

Wedbush reissued their outperform rating on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX  Free Report) in a research note issued to investors on Friday, Benzinga reports. The firm...

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MLTX
MoonLake Immunotherapeutics - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MLTX News

MLTX MoonLake Immunotherapeutics - Ordinary Shares - Class A